Article
The APRI may be enhanced by the use of the FIBROSpect II in the estimation of fibrosis in chronic hepatitis C.
Clinica chimica acta; international journal of clinical chemistry - 1 Jun 2007
Snyder Ned, Nguyen Audrey, Gajula Leka, Soloway Roger, Xiao Shu-Yuan, Lau Daryl T-Y, Petersen John
Abstract excerpt
BACKGROUND: Multiple serum markers to estimate hepatic fibrosis in chronic liver disease have been proposed. The AST/Platelet Ratio Index (APRI) is a simple biochemical index that has been shown to be useful and accurate in about 50% of patients with chronic hepatitis C. We determined if the combination of the APRI and the FIBROSpect II, a commercially available hepatic fibrosis marker that measures 3 components...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.